Previous 10 | Next 10 |
2023-08-30 08:20:15 ET Summary Radiopharmacy is expected to experience exponential growth over the next decade. Radiopharmaceutical-based therapies offer more targeted and specific approaches for cancer treatment and medical imaging, with prostate cancer proving to be a particular...
2023-08-18 08:43:41 ET More on Lantheus Lantheus: Pylarify And Definity Driving Strong Growth POINT Biopharma slips after pipeline update Lantheus prostate cancer diagnostics recommended for EU approval Lantheus soars 15% on Q1 beat, beats Q2 and FY forecast ...
2023-08-14 10:46:36 ET More on POINT Biopharma POINT Biopharma: Leading The Future Of Radioligand Therapy POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financ...
2023-08-03 16:16:02 ET Lantheus Holdings, Inc. (LNTH) Q2 2023 Earnings Conference Call August 03, 2023 08:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President ...
2023-08-03 09:05:43 ET Aravive ( ARAV ) -58% announces top-line results from phase 3 AXLerate-OC study of batiraxcept in patinum-resistant ovarian cancer. Vicarious Surgical ( RBOT ) -41% on pricing $45M offering . DXC Technology Company ( DXC ) -24% ...
2023-08-03 08:13:29 ET Lantheus Holdings ( NASDAQ: LNTH ) announced a divestiture of the sales-based royalty rights of its opioid antagonist RELISTOR. The company said the sale of this non-core asset allows it to focus on the core radiopharmaceutical business. HealthCare R...
2023-08-03 07:16:38 ET Lantheus press release ( NASDAQ: LNTH ): Q2 Non-GAAP EPS of $1.54 beats by $0.23 . Revenue of $321.7M (+43.8% Y/Y) beats by $15.04M . For further details see: Lantheus Non-GAAP EPS of $1.54 beats by $0.23, revenue of $321.7M beats b...
BEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians...
Worldwide revenue of $321.7 million for the second quarter 2023, representing an increase of 43.8% from the prior year period GAAP net income of $94.1 million for the second quarter 2023, compared to GAAP net income of $43.1 million in the prior year period GAAP fully diluted net ...
2023-08-02 16:12:02 ET Lantheus ( NASDAQ: LNTH ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is $1.31 (+47.2% Y/Y) and the consensus Revenue Estimate is $306.66M (+37.1% Y/Y). Over the last 2 year...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
16.4%Change Percent:
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acqu...